NEW YORK, March 22 (Reuters) - A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc, which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C.
Read more
No comments:
Post a Comment